Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 181

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 181
---
2023                                                               |     | F-5 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) for the Years Ended December 31, 2024, 2023 and 2022 |     | F-6 |
| Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Years Ended December 31, 2024, 2023 and 2022  |     | F-7 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022                                 |     | F-8 |
| Notes to the Consolidated Financial Statements                                                                             |     | F-9 |

<div align='center'>F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

| To: | The Board of Directors                
 and Shareholders of NewGenIvf Limited |

Opinion on the Financial Statements

We have audited the accompanying
consolidated balance sheets of NewGenIvf Limited and its subsidiaries (collectively the “Company”) as of December 31,
2021 and 2022, and the related consolidated statements of operations and comprehensive income (loss), changes in shareholders’
equity (deficit), and cash flows in each of the years for the two-year period ended December 31, 2022, and the related
notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2021 and 2022, and the results of its operations and its cash
flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally
accepted in the United States of America.

Restatement of Previously Issued Financial Statements

As discussed in Note 2,
the Company has restated its consolidated financial statements as of December 31, 2021 and 2022, and for the years then ended.

Correction of errors in the classification of subscription receivable

The Company had previously
erroneously presented subscription receivable as an asset; that classification was incorrect. According to Article 5-02.29 of Regulation
S-X, subscription receivable should be presented as a deduction from equity rather than an asset. The Company has reassessed the classification
of subscription receivable and has determined that it should be deducted from equity.

Recognition of directors’ rem